Real-World Study of Everolimus in Advanced Progressive Neuroendocrine TumorsFrancesco Panzuto, Gianfranco Delle Fave, Maria Rinzivillo et al.|The Oncologist|2014Cited by 103
Gastrointestinal stromal tumors: report of an audit and review of the literatureGuido Biasco, Fabio Farinati, Daniela Velo et al.|European Journal of Cancer Prevention|2009Cited by 51
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine TumorsFrancesco Panzuto, Gianfranco Delle Fave, Maria Rinzivillo et al.|The Oncologist|2015Cited by 9
Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)Stefano Cascinu, Rodolfo Passalacqua, G. Aprile et al.|Annals of Oncology|2015Cited by 0
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialAntonio Avallone, Umberto Malapelle, Claudio Lotesoriere et al.|Research Square|2025Cited by 0